Quattrini Cristian, Tavakoli Mitra, Jeziorska Maria, Kallinikos Panagiotis, Tesfaye Solomon, Finnigan Joanne, Marshall Andrew, Boulton Andrew J M, Efron Nathan, Malik Rayaz A
Division of Cardiovascular Medicine, University of Manchester, Manchester Diabetes Centre and Manchester Royal Infirmary, Manchester, UK.
Diabetes. 2007 Aug;56(8):2148-54. doi: 10.2337/db07-0285. Epub 2007 May 18.
Surrogate markers of diabetic neuropathy are being actively sought to facilitate the diagnosis, measure the progression, and assess the benefits of therapeutic intervention in patients with diabetic neuropathy. We have quantified small nerve fiber pathological changes using the technique of intraepidermal nerve fiber (IENF) assessment and the novel in vivo technique of corneal confocal microscopy (CCM). Fifty-four diabetic patients stratified for neuropathy, using neurological evaluation, neurophysiology, and quantitative sensory testing, and 15 control subjects were studied. They underwent a punch skin biopsy to quantify IENFs and CCM to quantify corneal nerve fibers. IENF density (IENFD), branch density, and branch length showed a progressive reduction with increasing severity of neuropathy, which was significant in patients with mild, moderate, and severe neuropathy. CCM also showed a progressive reduction in corneal nerve fiber density (CNFD) and branch density, but the latter was significantly reduced even in diabetic patients without neuropathy. Both IENFD and CNFD correlated significantly with cold detection and heat as pain thresholds. Intraepidermal and corneal nerve fiber lengths were reduced in patients with painful compared with painless diabetic neuropathy. Both IENF and CCM assessment accurately quantify small nerve fiber damage in diabetic patients. However, CCM quantifies small fiber damage rapidly and noninvasively and detects earlier stages of nerve damage compared with IENF pathology. This may make it an ideal technique to accurately diagnose and assess progression of human diabetic neuropathy.
目前正在积极寻找糖尿病神经病变的替代标志物,以促进糖尿病神经病变患者的诊断、监测病情进展并评估治疗干预的效果。我们已使用表皮内神经纤维(IENF)评估技术和新型的角膜共焦显微镜(CCM)体内技术对小神经纤维的病理变化进行了量化。研究对象包括54例根据神经学评估、神经生理学和定量感觉测试分层的糖尿病神经病变患者以及15名对照受试者。他们接受了皮肤打孔活检以量化IENF,并进行CCM以量化角膜神经纤维。随着神经病变严重程度的增加,IENF密度(IENFD)、分支密度和分支长度逐渐降低,在轻度、中度和重度神经病变患者中差异显著。CCM也显示角膜神经纤维密度(CNFD)和分支密度逐渐降低,但即使在无神经病变的糖尿病患者中,后者也显著降低。IENFD和CNFD均与冷觉检测和热痛阈值显著相关。与无痛性糖尿病神经病变患者相比,疼痛性糖尿病神经病变患者的表皮和角膜神经纤维长度缩短。IENF和CCM评估均能准确量化糖尿病患者的小神经纤维损伤。然而,与IENF病理学相比,CCM能快速、无创地量化小纤维损伤,并能检测到更早阶段的神经损伤。这可能使其成为准确诊断和评估人类糖尿病神经病变进展的理想技术。